Top BRD4 inhibition by ABBV-744 in cancer research studies Secrets
In Segment C, participants will get ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will get treatment until eventually ailment progression or the individuals are not able to tolerate the study drugs.88 These preclinical studies give paradigms for upcoming clinical trials in AML, and the u